Regenerative Therapy by Dr. Roshni Patel on Better CT – Farmington, CT – Patch.com

When youre in pain, its important to find effective, long-lasting solutions that can provide short recovery periods. This is what regenerative medicine offers. Over the past decade, there has been a growing field of medicine that utilizes the bodys own healing capabilities using platelet-rich plasma and mesenchymal stem cells (MSCs). This growing field is labeled as regenerative medicine. Regenerative therapies focus on healing and help regrow damaged tissue naturally. Regenerative injection therapy is used to provide relief to musculoskeletal injuries that involve damage to ligaments, tendons, cartilage, joints, and discs.

Watch video of PRP:

PRP therapy on Better CT

PRP is safeas we are using what your body naturally produces, concentrating the desired critical components and transplanting them into the affected area for effective tissue regeneration and healing. There is no risk of rejection and very minimal overall procedural risk.

FDA regulations do not allow for the cloning of stem cells or growing them in a lab. Also, stem cells derived from fat cells are not approved by the FDA as it does not allow for manipulation. This leaves us to another rich stem cell source in our body which is bone marrow. Stem cells exist in our bodies and are rudimentary cells that can differentiate into other cells.

Think of bone marrow stem cells as the mother cell that is responsible for producing new blood cells. Bone marrow contains hundreds of growth factors and is often used for severe degenerative conditions or where PRP therapy may not be sufficient to provide the growth factors needed to provide relief.

Lastly, there are many offshoot therapies that use biologics derived from placental tissue or blood cord. These biologics are sometimes marketed as Stem cells but are not stem cells and contain zero viable cells. What they contain are growth factors that can also aid when combined with PRP or Stem Cells derived from your own body.

MSCs and PRPmay be used to target a number of conditions that could benefit from their healing and regenerative qualities. Especially when considering chronic pain, alternative solutions may be necessary if it has been difficult to find relief. Along with generalized joint pain, MSCs and PRPmay be used to target:

With so many options for joint pain out there, you may be wondering what benefits choosing stem cell therapy provides. Overall, because mesenchymal stem cell therapy utilizes biologic material harvested directly from the patients body, the general benefits include minimal risk, minimal recovery time, and minimal worry:

Avoid surgery and its many complications and risks: Stem cell therapy is a minimally invasive, non-surgical procedure.

Minimal post-procedural recovery time: One of the most time-consuming factors of any injury is not always the treatment itself, but actually the recovery time. With stem cell therapy, recovery time is minimal.

No risk of rejection: Due to using biologics extracted from the patient, there is no risk of rejection.

No communicable disease transmission: As the cells originate within your own body, there is no risk of spreading disease from or to another person.

If you are suffering from joint pain, back pain, or a debilitating condition like osteoarthritis, it is important to consider all of your available options. Our elite team of professionals can determine if you are the right candidate for MSCs. If youre interested in learning more, contact us today.

See the article here:

Regenerative Therapy by Dr. Roshni Patel on Better CT - Farmington, CT - Patch.com

Read more
Four-Year Data Continue to Show Superior, Long-Term Survival Benefit with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Previously…

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot.

If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php

After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com.

View original post here:

Four-Year Data Continue to Show Superior, Long-Term Survival Benefit with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Previously...

Read more
The Top 10 Biotech Companies Brewing at… – Labiotech.eu

Here are the top biotech companies you will find in Oxford, a city with an old scientific tradition and an enormous output of biotech applications.

Oxford is well known for its university, one of the oldest in Europe and considered to be one of the best in the world. Recently, the University of Oxford has been the center of attention thanks to an experimental Covid-19 vaccine that the university is developing in partnership with big pharmaceutical companies. If successful, the vaccine, already in phase III testing, could be one of the first to get approval for this new disease.

The University of Oxford has hosted thousands of bright minds over the years. Thanks to its emphasis on technology transfer, the university has also helped a large number of them turn their ideas into successful spinout companies. The environment created around the university has also attracted many talents and businesses to the city, making it the ideal melting pot for new and promising ideas.

Biotech is one of the fortes of the innovation seen in the city of Oxford. So we consulted with local experts to put together a list of the most remarkable companies in the city, be it for their size, innovation, or influence in the sector.

Founded in 2008, Immunocore is one of just a few private biotech companies in Europe that are estimated to be worth over 1B. The company is tackling multiple forms of cancer as well as infectious and autoimmune diseases using T-cell receptor (TCR) technology. TCRs are proteins on the surface of immune T cells that are responsible for identifying a threat that must be destroyed, such as cancerous or infected cells. Immunocore aims to patients with engineered TCRs to circumvent the mechanisms by which these threats evade the immune system, restoring its ability to fight disease.

The company is collaborating on several projects with Genentech, AstraZeneca, Eli Lilly, and GSK. Its most advanced program is a treatment for uveal melanoma that is currently in phase III trials. Other programs target solid tumors, hepatitis, HIV, and type 1 diabetes.

Adaptimmune Therapeutics was founded at the same time as Immunocore with the goal of exploiting TCR technology in the form of T-cell therapy. The company engineers the TCRs naturally present on the patients own immune T cells to improve their ability to identify cancerous cells.

Adaptimmune is now getting ready to start late-stage clinical trials in multiple cancer types. Thanks to a deal with Astellas Pharma, the company is also gearing up to start clinical testing of a version of its T-cell therapy that doesnt require engineering each dose individually for each patient, using donor cells instead. Adaptimmune also has several partnerships with companies including GSK, Noile-Immune Biotech, and Alpine Immune Sciences.

Oxford Biodynamics was spun out of Oxford University in 2007 with the goal of developing liquid biopsy tests that can perform a diagnosis from just a drop of blood. The company specializes in epigenetics, that is changes to the structure of our DNA that determines which genes are switched on or off.

Oxford Biodynamics works in a wide range of indications, including cancer, diabetes, Alzheimers, multiple sclerosis, and rheumatoid arthritis among many others. The tests are not only designed to diagnose a disease; they can also be made to determine which patients are going to benefit the most from a specific drug, and how likely the disease is to progress faster or relapse.

With these tests, the company is supporting the development of personalized medicine approaches and helping drug developers increase their chances of succeeding in clinical trials. Partners include big pharma such as Pfizer and EMD, as well as universities and research institutes.

Chronos Therapeutics started out in 2009 as a spinout of the University of Oxford with the goal of developing drugs for age-related conditions. The companys lead program targets amyotrophic lateral sclerosis (ALS), the most common motor neuron disease, for which there are no treatments able to stop its progression.

Over time, the company has expanded its portfolio into other indications, particularly those that affect the brain, by acquiring assets from third parties. They include programs targeting fatigue caused by multiple sclerosis, addictive behaviors such as binge eating and alcohol use disorder, and post-traumatic stress disorder.

Evox Therapeutics is developing a drug delivery technology based on exosomes nanoparticles that our bodies naturally use to transport molecules. The company engineers exosomes to carry different types of drugs, such as proteins, RNA, or small drugs. The key advantage is that these natural carriers are able to reach targets that conventional drug delivery systems cant, such as the brain.

Founded in 2016, the company has signed big deals with Takeda and Eli Lilly. Its programs are all in preclinical testing and mostly target rare diseases. One of them targets the rare liver disorder argininosuccinic aciduria and is scheduled to enter clinical trials in 2021.

Exscientia is a pioneer in the application of artificial intelligence to drug discovery. The company uses AI to identify potential drug candidates and optimize their structure to maximize their chances of success in clinical trials. The goal is to speed up and reduce the costs of the drug discovery process.

Earlier this year, the companys drug candidate for obsessive-compulsive disorder became one of the first AI-designed drugs to enter clinical trials. While a drug typically takes five years from identification until clinical trials, this one did so in just a year.

Exscientia is partnered with Bayer, BMS, Sanofi, and GSk among others. In the wake of the Covid-19 pandemic, the company set out to go through a database of 15,000 approved and investigational drugs that had already passed safety testing to find candidates that can then be fast-tracked to clinical testing in Covid-19 patients.

Oxford Biomedica was set up in 1995 as a developer and provider of lentiviral vectors for gene and cell therapy. These vectors allow the permanent introduction of a desired DNA sequence into a target cell, be it in the test tube or directly in the patients body.

The technology of Oxford Biomedica is regularly used by companies such as Novartis, Sanofi, Boehringer Ingelheim, Imperial Innovations, and Orchard Therapeutics. Notably, the vectors developed by the company are used in Novartis Kymriah, the first CAR T-cell therapy approved in Europe and the US as a cancer treatment.

Oxford Biomedica also has a preclinical pipeline of proprietary programs in a wide range of applications, including cancer, eye disease, ALS, and liver disease. Last year, the company struck a deal with Microsoft to reduce the complexity and costs of gene and cell therapy manufacturing using artificial intelligence.

Founded in 2016, Arctoris aims to bring the benefits of automation to cancer research. Through the companys services, a researcher could just order an experiment online and spend their valuable time designing experiments and analyzing results rather than performing the repetitive tasks needed to complete them.

Arctoris aims to contribute to reducing the costs of drug discovery, which are increasing every year as treatments become personalized and results more difficult to replicate. In the context of the Covid-19 pandemic, Arctoris has established assays that allow scientists the possibility of running Covid-19 experiments remotely.

Founded in 2015, Orbit Discovery is a drug discovery company focusing on the identification of peptide drugs. The company has developed a technology that significantly improves on conventional methods of drug screening such as phage display or mRNA display.

The technology consists of fusing peptides to the DNA sequence encoding them and presenting them to live cells. This method allows the screening of peptide targets that were previously missed by other technologies, and to study their effect on live cells to better predict their function.

The company has already identified several candidates in the areas of cardiology, immunology, and cancer, and is working with partners such as Zealand Pharma in their preclinical development.

OxStem is a drug discovery company with an unusual approach to stem cell treatments. Instead of using stem cells as a therapy, the firm focuses on developing small molecule drugs that can reprogram the patients own stem cells to treat a wide range of diseases related to aging, including cancer and diabetes as well as neurological, cardiovascular, and ocular conditions.

Founded in 2013, the strategy of OxStem is to spin out companies that specialize in each disease area to focus on the development of the drugs found by the parent company, with five subsidiaries set up so far.

Original post:

The Top 10 Biotech Companies Brewing at... - Labiotech.eu

Read more
CRISPR Market to Witness Exponential Growth by 2020-2027 | Leading Players Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR…

Fort Collins, Colorado The report on the CRISPR Market provides an in-depth assessment of the CRISPR market including technological advancements, market drivers, challenges, current and emerging trends, opportunities, threats, risks, strategic developments, product advancements, and other key features. The report covers market size estimation, share, growth rate, global position, and regional analysis of the market. The report also covers forecast estimations for investments in the CRISPR industry from 2020 to 2027.

The report is furnished with the latest market dynamics and economic scenario in regards to the COVID-19 pandemic. The pandemic has brought about drastic changes in the economy of the world and has affected several key segments and growth opportunities. The report provides an in-depth impact analysis of the pandemic on the market to better understand the latest changes in the market and gain a futuristic outlook on a post-COVID-19 scenario.

Global CRISPR Market Size Study by Application(Genome Editing, Genetic Engineering, Gene Library, CRISPR Plasmid, Human Stem cells, Genetically Modified Organism, Cell Line Engineering), by End-User (Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research & Development Institutes) and Regional Forecast 2017-2025.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=5977

The report provides an in-depth analysis of the key developments and innovations of the market, such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report provides a comprehensive overview of the regional growth of each market player.

Additionally, the report provides details about the revenue estimation, financial standings, capacity, import/export, supply and demand ratio, production and consumption trends, CAGR, market share, market growth dynamics, and market segmentation analysis.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Furthermore, the report utilizes advanced analytical tools such as SWOT analysis and Porters Five Forces Analysis to analyze key industry players and their market scope. The report also provides feasibility analysis and investment return analysis. It also provides strategic recommendations to formulate investment strategies and provides insights for new entrants.

Request a discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=5977

The report is designed with an aim to assist the reader in taking beneficial data and making fruitful decisions to accelerate their businesses. The report provides an examination of the economic scenario, along with benefits, limitations, supply, production, demands, and development rate of the market.

By Applications:

By End User:

Request customization of the report @https://reportsglobe.com/need-customization/?rid=5977

Regional Analysis of the Market:

For a better understanding of the global CRISPR market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread acrossNorth America, Europe, Latin America, Asia-Pacific, and Middle East & Africa.Each region is analyzed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market.

Benefits of the Global CRISPR Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-crispr-market/

Thank you for reading our report. To learn more about report details or for customization information, please contact us. Our team will ensure that the report is customized according to your requirements.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

More here:

CRISPR Market to Witness Exponential Growth by 2020-2027 | Leading Players Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR...

Read more
Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322 – Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the bodys innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today presented clinical results from a longer-term durability study of FX-322, showing that some patients with chronic sensorineural hearing loss had significant improvement in key measures of hearing that were sustained for up to 21 months.

These new data build upon Phase 1/2 study results previously detailed at the 2019 AAO-HNS conference that showed, for the first time, statistically significant improvements in word recognition (WR) scores in patients with chronic moderate to moderately severe SNHL. These patients had received a single intratympanic dose of FX-322 in a double-blind, placebo-controlled study, and had been evaluated for 90 days. Subsequent testing of a subset of these patients between 13 and 21 months after initial dosing, showed sustained improvements in measures of speech intelligibility (clarity), and in some patients, increased audibility (volume) threshold values at a higher frequency. Susan King, M.D., FACS, the lead investigator on both studies, detailed results today at the AAO-HNSF 2020 Virtual Annual Meeting & OTO Experience.

Historically, patients with acquired chronic SNHL do not regain their lost hearing. The FX-322 Phase 1/2 study has provided promising evidence of clinically meaningful improvements in word recognition, and based on the recent longer-term follow-up data, we believe that this benefit may be sustained for many months following a single dose of this investigational treatment, said Dr. King, co-founder of the Ear Medical Group in San Antonio and Clinical Professor, Department of Otolaryngology, Head and Neck Surgery, The University of Texas Health Science Center at San Antonio. It is exciting to see sustained clinical benefits in these individuals, and while still early, also to see the potential for a therapeutic that may provide sustained speech intelligibility improvement, which remains an unmet need for hearing loss patients.

Four of the patients that were observed to have statistically significant WR scores during the Phase 1/2 study had maintained those improvements in the follow up assessment. Three of these patients remained at statistically significant levels, maintaining an average increase of 87 percent in WR scores from their original baseline levels. The other patient maintained a 71 percent increase from their initial baseline, though that sustained improvement fell outside the range of statistical significance. An additional patient who did not achieve statistically significant change in WR during the Phase 1/2 study was also retested, and it was observed that their WR score had returned to baseline.

Moreover, three of the patients that maintained statistically significant WR scores also showed 10-15dB improvements at 8000Hz compared to their original threshold values at this frequency. The safety profile observed in the FX-322 Phase 1/2 study was favorable and no additional safety findings were observed in the follow-up period. Together, these longer-term clinical data demonstrate the potential for FX-322 to have a durable positive impact both on measures of hearing clarity and volume.

Todays announcement is another important building block as we further our understanding of FX-322s drug potential and the patient populations we hope to treat. In addition to a favorable safety profile, we have generated compelling cochlear drug delivery data, and these newly presented results show that the FX-322 benefit to hearing loss may provide individuals with a long-lasting clinical benefit, said David L. Lucchino, Frequencys chief executive officer. Furthermore, we believe this provides additional evidence supporting the regenerative mechanism of our novel therapeutic approach and a potentially disease modifying treatment. We look forward to sharing data from our ongoing Phase 2a study and to a better understanding of the impact of FX-322 on sound clarity and word recognition that is so critical to hearing health and overall health.

About FX-322 and Sensorineural Hearing Loss

FX-322 is Frequencys lead product candidate for the treatment of acquired SNHL. SNHL impacts more than 40 million people in the U.S. and hundreds of millions of people globally and is the primary cause of more than 90 percent of all hearing loss. Acquired SNHL typically results from damage to the hair cells of the inner ear into signals that are sent to the brain. These auditory sensory hair cells may be lost due to chronic noise exposure, aging, certain viral infections or exposure to drugs that are toxic to the ear. FX-322 is designed to activate progenitor cells (pre-programmed stem cells) and regenerate auditory hair cells in the inner ear (cochlea) to restore hearing function.

FX-322 is currently being evaluated in a Phase 2a study. The FX-322 Phase 2a study is a randomized, double blind, placebo-controlled, single- and repeat-dose study in which the Company plans to enroll up to 96 patients aged 18 to 65 with SNHL. The objectives of the Phase 2a study are to further establish the hearing signal observed in the completed Phase 1/2 study, evaluate the impact of multiple doses and provide deeper insights on endpoints and the appropriate patient population for future studies. FX-322 Phase 2a study subjects are randomized to receive either FX-322 or placebo in one ear, with the untreated ear acting as an additional measure of control. The study is using validated measures of hearing function including word recognition (WR), words-in-noise and pure tone audiometry. Tinnitus and quality-of-life measures will also be evaluated using the Tinnitus Functional Index and the Hearing Handicap Inventory for Adults, respectively. The Phase 2a study has four dose cohorts, and hearing function will be regularly tested over the course of seven months following the first dosing.

The FX-322 Phase 2a study remains ongoing and the Company is expected to report study data in the second quarter of 2021.

About Frequency Therapeutics

Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Companys progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Companys lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. In a FX-322 Phase 1/2 study, statistically significant and clinically meaningful improvements in key measures of hearing function in patients with sensorineural hearing loss were observed. FX-322 is being evaluated in an ongoing Phase 2a clinical study in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including a discovery program in multiple sclerosis.

Headquartered in Woburn, Mass., Frequency has a license and collaboration agreement with Astellas Pharma Inc. for FX-322, for which it retains U.S. rights, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including The Scripps Research Institute, Massachusetts Eye and Ear, Mass General Brigham and the Massachusetts Institute of Technology. For more information, visit http://www.frequencytx.com and follow Frequency on Twitter @Frequencytx.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Phase 2a clinical trial, pace and timing of enrollment for the Phase 2a clinical trial, the timing of top-line data from the Phase 2a clinical trial, the results and implications of the Phase 1/2 durability of response data, the ability of our technology platform to provide patient benefit, the impact of COVID-19 on the Companys on-going and planned clinical trials and business, increases in headcount, future milestone and royalty payments under the license and collaboration agreement with Astellas, estimates of the size of the hearing loss population and population at risk for hearing loss, the Companys ability to advance its hearing program and further diversify its portfolio and the potential application of the PCA platform to other diseases.

These forward-looking statements are based on managements current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of COVID-19 on the Companys ongoing and planned clinical trials, research and development and manufacturing activities, the relocation of the Companys offices and laboratory facilities, the Companys business and financial markets; the Company has incurred and will continue to incur significant losses and is not and may never be profitable; the Companys need for additional funding to complete development and commercialization of any product candidate; the Companys dependence on the development of FX-322; the unproven approach of the PCA platform; the lengthy, expensive and uncertain process of clinical drug development and regulatory approval; limited experience successfully obtaining marketing approval for and commercializing product candidates; the results of earlier clinical trials not being indicative of the results from later clinical trials; differences between preliminary or interim data and final data; adverse events or undesirable side effects; disruptions at the FDA and other regulatory agencies; failure to identify additional product candidates; new or changed legislation; failure to maintain Fast Track designation for FX-322 and such designation failing to result in faster development or regulatory review or approval; costly and damaging litigation, including related to product liability or intellectual property or brought by stockholders; dependence on Astellas Pharma Inc. for the development and commercialization of FX-322 outside of the United States; misconduct by employees or independent contractors; reliance on third parties, including to conduct clinical trials and manufacture product candidates; compliance with laws and regulations, including healthcare and environmental, health, and safety laws and regulations; failure to obtain, maintain and enforce protection of patents and other intellectual property; security breaches or failure to protect private personal information; attracting and retaining key personnel; and ability to manage growth.

These and other important factors discussed under the caption Risk factors in the Companys Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 12, 2020 and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date of this press release.

More here:

Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322 - Business Wire

Read more
Faulty exon splicing is cause of rare subtype of Parkinson’s disease, pointing to new drug targets – BioWorld Online

The value of patient-based cell models and brain organoids in unpicking the complexities of neurodegenerative diseases is again highlighted in new research showing how mutations that cause a rare subtype of Parkinson's disease operate at a cellular level.

Using stem cells derived from members of families carrying mutations in the PARK7 gene that are linked to an early onset form of Parkinson's disease, the researchers at the University of Luxembourg directly observed that these defects disrupt exon splicing.

That interferes with the activity of a small RNA called U1, reducing production of the DJ-1 protein (also called Parkinsonism associated deglycase), which among other functions, is involved in mitochondrial regulation. The researchers found that mitochondria in the patient-derived cell models malfunctioned as a result.

Based on this insight, Ibrahim Boussaad and colleagues designed a combination therapy that repaired these aberrations, halting the death of dopaminergic neurons in brain organoids.

The researchers say the study, published in the latest issue of Science Translational Medicine, provides a foundation to develop therapies that could help correct the genetic cause of some forms of Parkinson's disease.

"When PARK7 was first discovered it was described as causing the substitution of an amino acid. It's only when we got patient material we could see it's not substitution. We saw it was a problem with splicing," Boussaad told BioWorld Science.

There are more than 25 PARK7 gene mutations that are implicated in Parkinson's disease. However, it previously was unclear how loss of functional DJ-1 protein causes the neurodegenerative disease, with some studies suggesting PARK7 mutations disrupt the protein's chaperone function, leading to a toxic buildup of misfolded proteins, while others suggest PARK7 mutations impair DJ-1's ability to protect cells from oxidative stress.

Boussaad said the researchers were aiming to pinpoint specific defects in the mutant DJ-1 protein generated by the patient cell models. Instead, they found there was little or no trace of the protein at all.

The possibility that the protein was unstable and had degenerated was excluded by blocking degradation pathways to show there were no metabolites of the protein.

"So we took a step back and started to look upstream. We could detect [PARK7] RNA, but it was shorter," said Boussaad. "On sequencing the products, we saw an entire section of RNA was missing."

Luckily, one of the donors was heterozygous for PARK7, and in this case it was possible to detect both normal length and shorter RNA, helping to confirm that mis-splicing was blocking DJ-1 production.

The researchers showed it was possible to correct the defective exon skipping using genetically engineered U1-snRNA (small nuclear RNA). That corrected DJ-1 expression in neuronal precursor cells and differentiated neurons.

They also demonstrated that combination treatment with the small molecules RECTAS (rectifier of aberrant splicing) and phenylbutyric acid repaired the splicing defects, restoring DJ-1 production, correcting mitochondrial function and preventing loss of dopaminergic cells in mutant PARK7 brain organoids.

Looking at sequence databases, the researchers found that similar splicing mutations appeared more frequently in the genomic data from 2,710 patients with the common sporadic form of Parkinson's disease, than in data from 5,713 controls, pointing to a wider significance of the current study.

With the literature suggesting that as many as a third of all disease-causing mutations exert their effects through faulty exon splicing, the findings could also have relevance to other conditions.

The direct observation of the cellular-level impact of one of these mutations and the possibility of therapeutic intervention, should lead to greater focus in this area, Boussaad said. "There are a few other such mutations known and described, but they have not got the attention they should have in the field of neurodegenerative diseases."

As a next step, the researchers plan to further develop the combination treatment. "We are going into animal models to see how potent it is in entire organisms. We also want to look at availability in the brain and if compounds have the ability to cross the blood-brain barrier," said Boussaad. "And of course, the other direction will be to further explore the abundance of exon splicing mutations in Parkinson's disease."

It is becoming increasingly clear that although patients with Parkinson's present with the same motor symptoms, there are subtypes of the disease which have different etiologies. "To advance treatment, we have to stratify. We have to investigate for each patient, why they have this disease," Boussaad said.

That could form the basis of customized treatments. "If we can identify patients with exon splicing mutations it will have positive benefits. If they can be corrected, it will restore the protein and be neuroprotective, rather than treating the symptoms," said Boussaad. "It could have a significant impact." (Boussaad, I. et al. Sci Transl Med 2020, 12: eaau3960).

Read the original post:

Faulty exon splicing is cause of rare subtype of Parkinson's disease, pointing to new drug targets - BioWorld Online

Read more
Treating dogs diagnosed with GBM, getting Swedish patients back to work, orphan designation for improved radiotherapy drug plus gene therapy – Brain…

We know that dogs can be diagnosed with brain tumours however this is the first time we have reported on positive results in a preliminary brain cancer study for the treatment of dogs. Animal Life Sciences, Inc. (ALS), a pharmaceutical and nutritional development company announced that a comparative oncology trial being conducted using ALS101( a combination of two brain cancer drug candidates ALS licensed for use in animals) is showing promise in dogs suffering from malignant gliomas, including glioblastoma. Dogs suffer from these same types of aggressive tumours and treatment options, much like those for humans, are extremely limited. ALS have seen regression of tumour in a significant population of dogs treated in a formal Phase I clinical trial and while the tumour did not quite disappear, in some cases it shrank more than 95 percent and the animals lived longer.

News from Sweden now where a study has shown that one year after the diagnosis of low-grade malignant brain tumour just under three people in ten were in full-time employment. For this young patient group, returning to work is a key health factor however another year later, the proportion remained below half. For those of you unsure about the characterisation of a low grade, malignant tumour it is defined in this study as a low-grade glioma which is incurable and grows slowly but, thanks to modern treatments, its survival expectancy has successively increased. Given the patients' low age -- averaging 40 years when they fell ill -- their work capacity is seen as an especially important factor in quality of life. Being able to work again is, for many, a crucial aspect of returning to a normal life.

We have explained about orphan drug diagnosis in these updates before but to recap, in the US the Orphan Drug Act (ODA) provides for granting special status to a drug to treat a rare disease or condition. Benefits for a pharma company of having a drug given orphan designation include tax credits of 50% off the clinical drug testing cost awarded upon approval and eligibility for market exclusivity for 7 years post-approval.

Plus Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for its lead investigational drug, Rhenium NanoLiposomes (RNL) for the treatment of patients with recurrent glioblastoma. RNL is designed to safely, effectively, and conveniently deliver a very high dose of radiation - up to 25 times greater concentration than currently used external beam radiation therapy - directly into the brain tumour for maximum effect. Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics said: We believe RNL has the potential to prolong survival for patients with malignant brain tumours and that of other difficult to treat radiosensitive tumours.

In the fight against cancer, scientists have long grappled with the ambiguous nature of stem cells. GBM tumours consist of stem cells which have the ability to self-renew making these tumours notoriously hard to treat with targeted radiation therapy and difficult to permanently remove through surgery. However, could gene therapy provide a potential breakthrough in brain cancer treatment and put the invincibility of tumour stem cells into question. This recent paper details a new technique of sensitizing stem cells to radiation therapy, thereby increasing the therapys efficacy.

You may find this overview of dendritic cell vaccines for brain tumours is helpful reading before moving onto this paperOnce, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. John Sampson, M.D., Ph.D. from Duke University a leader in cancer immunotherapy for brain tumours commented on the paper saying These study results not only advance our understanding of a virus role in cancer, but they also signal tremendous hope to patients and their families suffering from this devastating disease

An optimistic-sounding end to this weeks worldwide research update.

Related reading:

If you found this story interesting or helpful, sign up to our weekly e-newsand keep up to date with all the latest from Brain Tumour Research.

See more here:

Treating dogs diagnosed with GBM, getting Swedish patients back to work, orphan designation for improved radiotherapy drug plus gene therapy - Brain...

Read more
Histogen Announces Completion of Dosing Milestone in its 1b/2a Trial for Androgenic Alopecia in Men – StreetInsider.com

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot.

If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php

After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com.

Excerpt from:

Histogen Announces Completion of Dosing Milestone in its 1b/2a Trial for Androgenic Alopecia in Men - StreetInsider.com

Read more
BeyondSpring (BYSI) Receives Breakthrough Therapy Designations from Both US FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia…

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot.

If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php

After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com.

See original here:

BeyondSpring (BYSI) Receives Breakthrough Therapy Designations from Both US FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia...

Read more